BTMD Stock Overview
Operates in practice-building business within the hormone optimization space. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
biote Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.39 |
| 52 Week High | US$8.44 |
| 52 Week Low | US$3.65 |
| Beta | 0.94 |
| 11 Month Change | 1.32% |
| 3 Month Change | -4.09% |
| 1 Year Change | 6.52% |
| 33 Year Change | -44.72% |
| 5 Year Change | n/a |
| Change since IPO | -46.37% |
Recent News & Updates
Shareholder Returns
| BTMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.3% | -5.7% | -2.1% |
| 1Y | 6.5% | 9.0% | 29.6% |
Return vs Industry: BTMD underperformed the US Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: BTMD underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| BTMD volatility | |
|---|---|
| BTMD Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BTMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BTMD's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 194 | Terry Weber | biote.com |
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
biote Corp. Fundamentals Summary
| BTMD fundamental statistics | |
|---|---|
| Market cap | US$195.84m |
| Earnings (TTM) | US$7.19m |
| Revenue (TTM) | US$193.06m |
23.3x
P/E Ratio0.9x
P/S RatioIs BTMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTMD income statement (TTM) | |
|---|---|
| Revenue | US$193.06m |
| Cost of Revenue | US$57.83m |
| Gross Profit | US$135.23m |
| Other Expenses | US$128.04m |
| Earnings | US$7.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 70.05% |
| Net Profit Margin | 3.72% |
| Debt/Equity Ratio | -93.7% |
How did BTMD perform over the long term?
See historical performance and comparison